Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | TLR2 | O60603 | 3/20 | 0.38 |
| ▸ | TLR1 | Q15399 | 1/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.37 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27428823 | 1.00 | PSMB8 (0.40) | PSMB8PSMB9PSMB5PAX8TDP1 | |
| SCHEMBL27429188 | 0.93 | ITGB3 (0.38) | CA1CA2PTPN1ITGB3ITGA2B | |
| SCHEMBL27428989 | 0.90 | CCKBR (0.40) | PSMB8PSMB9PSMB5 | |
| SCHEMBL27434029 | 0.90 | CCKBR (0.40) | PSMB8PSMB9PSMB5 | |
| SCHEMBL27433823 | 0.88 | CA1 (0.36) | CA1CA2TLR2TLR1 | |
| SCHEMBL27433897 | 0.87 | PSMB8 (0.42) | PSMB8PSMB9PSMB5PAX8TDP1 | |
| SCHEMBL27389363 | 0.84 | CA1 (0.42) | PAX8TDP1CA1CA2PTPN1 | |
| SCHEMBL27433907 | 0.84 | CA1 (0.42) | PAX8TDP1CA1CA2PTPN1 | |
| SCHEMBL30918335 | 0.84 | PTPN1 (0.42) | TLR2PTPN1 | |
| SCHEMBL27428871 | 0.83 | CCKBR (0.37) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | JANSSEN PHARMACEUTICA NV (BE) | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240218014-A1 | SYNTHESIS OF A CYCLIC PEPTIDE | VIP, QPCT, PTMS | PSMB8 1489/4885PSMB9 1526/4885PSMB5 1767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.